Clinical Trial Finder

Hundreds of clinical trials are rolled out around the world monthly, and many of them are designed to specifically uncover and manage the medical needs of people with sickle cell disease and trait. We keep an updated list of these global studies here, so you don’t have to go searching for them. There might be active study recruitment and enrollment happening at a site near you. Explore the list below to see the different types of studies, and use the navigation options on the left to get as specific as you would like.

Filters
Sort by
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell Disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of treatment with EDIT-301 in adult subjects with severe sickle cell disease (SCD).

Locations

16 United States sites

3 Canada sites

Age

18 Years - 50 Years

Phase

Phase 1/Phase 2

LEARN MORE
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).

Locations

49 United States sites

5 France sites

5 Spain sites

4 Greece sites

4 Italy sites

4 United Kingdom sites

3 Canada sites

2 Lebanon sites

2 Germany sites

Age

12 Years - 65 Years

Phase

Phase 2/Phase 3

LEARN MORE
A First-in-patient Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell Disease

This study is evaluating a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle cell disease.

Locations

4 United States sites

1 Italy site

Age

2 Years - 40 Years

Genotypes

HbSS, HbSC

Phase

Phase 1/Phase 2

LEARN MORE
Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients With Severe Sickle Cell Disease

This study is being done to test a transplant method that may have fewer side effects (or less toxic, less harmful) than conventional high dose chemotherapy conditioning-based transplants for children and young adults with Sickle Cell Disease (SCD).

Locations

1 United States site

Age

2 Years - 25 Years

Phase

Phase 2

LEARN MORE
Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia

The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients.

Locations

4 United States sites

Age

5 Years - 50 Years

Genotypes

SCA, HbSS

LEARN MORE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease

This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to < 15 years old, with Sickle Cell Disease.

Locations

17 United States sites

5 Nigeria sites

4 Egypt sites

4 Kenya sites

4 United Kingdom sites

3 Italy sites

2 Ghana sites

2 Oman sites

2 Saudi Arabia sites

1 France site

Age

2 Years - 14 Years

Genotypes

SCA

Phase

Phase 3

LEARN MORE
Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Healthcare Transition

Children with sickle cell disease (SCD) are living longer with the advent of medical advances such as prophylactic penicillin, chronic transfusion, and hydroxyurea.

Locations

2 United States sites

Age

16 Years - 20 Years

LEARN MORE
The Pro-Inflammatory Effects of Acute Exercise in Children With Sickle Cell Anemia

Recommendations for exercise prescription currently do not exist for individuals with sickle cell anemia (SCA) despite the known impact that SCA-related complications has on physical functioning and fitness.

Locations

4 United States sites

Age

10 Years - 21 Years

Genotypes

hemoglobin SS

LEARN MORE
Engaging Parents of Children With Sickle Cell Anemia and Their Providers in Shared-Decision Making for Hydroxyurea (ENGAGE HU)

The goal of the study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that takes into account medical evidence and parent values and preferences).

Locations

11 United States sites

Age

1 Month - 5 Years

Phase

Not Applicable

LEARN MORE
The Epidemiology of Silent and Overt Strokes in Adults With Sickle Cell Disease: a Prospective Cohort Study

Sickle Cell Disease (SCD) is a rare disease occurring in an estimated 100,000 individuals, often poor and underserved, in the US.

Locations

4 United States sites

Age

> 18 Years

Genotypes

SCA

LEARN MORE